Metastatic castration-resistant prostate cancer
AR-NTDShuts down androgen receptor signalling that current therapies leave intact.
Peptone is building a Product Engine to generate small-molecule drug candidates against intrinsically disordered proteins
Peptone's Product Engine reads the physics of disordered proteins and models it with AI. We use those insights to design small-molecule drug candidates for hard-to-treat cancers.
Disordered proteins never stand still. We map their dynamics, reveal transient pockets, and design small-molecule drug candidates to target them.
Shuts down androgen receptor signalling that current therapies leave intact.
Engages a transcription factor long considered undruggable.
Holds the disordered low-complexity domain in soluble, aggregation-resistant states.